- Home
- ERIE vs INCY Comparison
ERIE vs INCY Comparison
Compare ERIE & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERIE | INCY |
|---|---|---|
| Founded | 1925 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 17.0B |
| IPO Year | 1995 | 1993 |
Fundamental Metrics
Financial Performance| Metric | ERIE | INCY |
|---|---|---|
| Price | $295.79 | $104.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $90.71 |
| AVG Volume (30 Days) | 153.3K | ★ 2.3M |
| Earning Date | 10-30-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | 15.90 | ★ 3878.02 |
| EPS | ★ 12.39 | 5.90 |
| Revenue | $4,040,325,000.00 | ★ $4,813,105,000.00 |
| Revenue This Year | $10.96 | $19.33 |
| Revenue Next Year | $8.12 | $10.47 |
| P/E Ratio | $23.84 | ★ $17.70 |
| Revenue Growth | 9.53 | ★ 18.09 |
| 52 Week Low | $276.91 | $53.56 |
| 52 Week High | $456.93 | $109.28 |
Technical Indicators
Market Signals| Indicator | ERIE | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 62.26 |
| Support Level | $291.59 | $100.30 |
| Resistance Level | $298.79 | $107.61 |
| Average True Range (ATR) | 6.38 | 3.01 |
| MACD | 2.35 | -0.57 |
| Stochastic Oscillator | 75.63 | 49.03 |
Price Performance
Historical ComparisonAbout ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.